The U-BIOPRED (Unbiased BIOmarkers in PREDiction of respiratory disease outcomes) outcomes, in which EFA contributed, have been summarised in an interview published by European Respiratory & Pulmonary Diseases. Professor Ian Adcock, principal investigator for U-BIOPRED is the one explaining the latest outcomes.
U-BIOPRED is a European consortium of over 20 academic institutions, 11 pharmaceutical companies and six patient organisations. EFA, along with two of its members Asthma UK and LongFonds, and together with the European Lung Foundation represent these patients organisations. U-BIOPRED study addresses knowledge gaps for severe asthma and seeks to identify new treatments along with best ways to make such treatments available to the general public.
We brought the patient perspective to the project, not only concerning ethics but also ensuring patients access to information on the project and positioning it as a best practice on patient involvement in respiratory research.
Read the whole interview here
Funded under the European Commission’s 7th Framework Innovative Medicines Initiative (IMI), U-BIOPRED “Unbiased BIOmarkers in PREDiction of respiratory disease outcomes” has increased the understanding of severe asthma in order to develop more effective interventions for people living with the condition. Learn more about the project